Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819227) titled 'Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University Medical Center Groningen
Condition:
Chronic Kidney Disease
Intervention:
Drug: Finerenone (BAY 94-8862)
Drug: Semaglutide 14 MG [Rybelsus]
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 11, 2025
Target Sample Size: 41
Countries of Recruitment:
Denmark
Italy
Netherlands
Spain
Denmark
Italy
Neth...